JP6735277B2 - 乳癌療法剤に対する反応を予測するための方法および乳癌の処置の方法 - Google Patents
乳癌療法剤に対する反応を予測するための方法および乳癌の処置の方法 Download PDFInfo
- Publication number
- JP6735277B2 JP6735277B2 JP2017531209A JP2017531209A JP6735277B2 JP 6735277 B2 JP6735277 B2 JP 6735277B2 JP 2017531209 A JP2017531209 A JP 2017531209A JP 2017531209 A JP2017531209 A JP 2017531209A JP 6735277 B2 JP6735277 B2 JP 6735277B2
- Authority
- JP
- Japan
- Prior art keywords
- basal
- luminal
- breast cancer
- classifier score
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462091195P | 2014-12-12 | 2014-12-12 | |
US62/091,195 | 2014-12-12 | ||
US201562142504P | 2015-04-03 | 2015-04-03 | |
US62/142,504 | 2015-04-03 | ||
US201562167110P | 2015-05-27 | 2015-05-27 | |
US62/167,110 | 2015-05-27 | ||
PCT/US2015/064500 WO2016094408A1 (en) | 2014-12-12 | 2015-12-08 | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018504892A JP2018504892A (ja) | 2018-02-22 |
JP2018504892A5 JP2018504892A5 (pt) | 2019-01-24 |
JP6735277B2 true JP6735277B2 (ja) | 2020-08-05 |
Family
ID=55273509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017531209A Active JP6735277B2 (ja) | 2014-12-12 | 2015-12-08 | 乳癌療法剤に対する反応を予測するための方法および乳癌の処置の方法 |
Country Status (15)
Country | Link |
---|---|
US (3) | US10196693B2 (pt) |
EP (2) | EP3604556A1 (pt) |
JP (1) | JP6735277B2 (pt) |
KR (1) | KR20170095306A (pt) |
CN (1) | CN107109488A (pt) |
AU (1) | AU2015360767A1 (pt) |
BR (1) | BR112017012142A2 (pt) |
CA (1) | CA2970469A1 (pt) |
ES (1) | ES2748005T3 (pt) |
IL (1) | IL252587A0 (pt) |
MX (1) | MX2017007707A (pt) |
RU (1) | RU2017120330A (pt) |
SG (1) | SG11201704425TA (pt) |
WO (1) | WO2016094408A1 (pt) |
ZA (1) | ZA201703904B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013066440A1 (en) | 2011-07-29 | 2013-05-10 | Medivation Prostate Therapeutics, Inc. | Treatment of breast cancer |
US20140243211A1 (en) | 2013-02-28 | 2014-08-28 | Indiana University Research & Technology Corporation | Blood biomarkers for suicidality |
US10196693B2 (en) | 2014-12-12 | 2019-02-05 | Medivation Prostate Therapeutics Llc | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer |
AU2016274988A1 (en) | 2015-06-12 | 2017-12-21 | Indiana University Research & Technology Corporation | Predicting suicidality using a combined genomic and clinical risk assessment |
KR101966493B1 (ko) * | 2016-06-27 | 2019-04-05 | 국립암센터 | 삼중음성유방암 예후 예측용 바이오마커 |
KR101896558B1 (ko) * | 2016-11-21 | 2018-09-07 | 주식회사 젠큐릭스 | 유방암 환자의 예후 예측 방법 |
US20200064556A1 (en) * | 2017-04-26 | 2020-02-27 | Nippon Telegraph And Telephone Corporation | NxN Optical Switch |
WO2018209341A1 (en) | 2017-05-12 | 2018-11-15 | Indiana University Research And Technology Corporation | Precision medicine for treating and preventing suicidality |
RU2648523C1 (ru) * | 2017-05-22 | 2018-03-26 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") | Способ прогнозирования исхода заболевания у больных люминальным в и трижды негативным раком молочной железы у пациенток, не получавших в неоадъювантном режиме химио- или гормонотерапию |
WO2020001473A1 (zh) * | 2018-06-28 | 2020-01-02 | 复旦大学 | 小核仁核糖核酸snord33作为生物标记物用于制备检测试剂盒中的用途 |
CN109735625A (zh) * | 2019-03-18 | 2019-05-10 | 马榕 | 乳头溢液在检测肿瘤相关基因中的应用 |
WO2024035653A1 (en) * | 2022-08-06 | 2024-02-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Predictive biomarker in avastin in colon cancer |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
EP1027456B1 (en) | 1997-10-31 | 2005-03-16 | Affymetrix, Inc. (a Delaware Corporation) | Expression profiles in adult and fetal organs |
US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
US6937713B1 (en) | 1999-12-30 | 2005-08-30 | At&T Corp. | IP call forward profile |
US7504222B2 (en) | 2001-10-31 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
US20070192880A1 (en) | 2003-10-03 | 2007-08-16 | University Of Rochester | Horming response element binding transregulators |
US20070059720A9 (en) | 2004-12-06 | 2007-03-15 | Suzanne Fuqua | RNA expression profile predicting response to tamoxifen in breast cancer patients |
EP3970721A1 (en) | 2005-05-13 | 2022-03-23 | The Regents Of The University Of California | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer |
US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
WO2007061876A2 (en) | 2005-11-23 | 2007-05-31 | University Of Utah Research Foundation | Methods and compositions involving intrinsic genes |
EP2004181B3 (en) | 2006-03-27 | 2023-05-24 | The Regents Of The University Of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
US8110594B2 (en) | 2006-03-29 | 2012-02-07 | The Regents Of The University Of California | Diarylthiohydantoin compounds |
CA2966280A1 (en) | 2007-10-26 | 2009-04-30 | The Regents Of The University Of California | Diarylhydantoin compounds |
CN103169973A (zh) * | 2007-11-12 | 2013-06-26 | 彼帕科学公司 | 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌 |
US8450290B2 (en) | 2007-11-26 | 2013-05-28 | Enzon Pharmaceuticals, Inc. | Methods for treating androgen receptor dependent disorders including cancers |
WO2009114534A1 (en) | 2008-03-14 | 2009-09-17 | The Regents Of The University Of California | Multi-gene classifiers and prognostic indicators for cancers |
WO2009158143A1 (en) | 2008-05-30 | 2009-12-30 | The University Of North Carolina At Chapel Hill | Gene expression profiles to predict breast cancer outcomes |
EP2400847B1 (en) | 2009-02-24 | 2014-12-17 | Medivation Prostate Therapeutics, Inc. | Specific diarylthiohydantoin compounds |
US8710086B2 (en) | 2009-04-09 | 2014-04-29 | Medivation Technologies, Inc. | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof |
EP2425015B1 (en) | 2009-04-29 | 2018-01-10 | Ralph Wirtz | A method to assess prognosis and to predict therapeutic success in cancer by determining hormone receptor expression levels |
US8507195B2 (en) | 2009-08-20 | 2013-08-13 | The Regents Of The University Of Colorado | MiRNAs dysregulated in triple-negative breast cancer |
US20120178094A1 (en) | 2009-09-03 | 2012-07-12 | Peter Kuhn | Method for Categorizing Circulating Tumor Cells |
EP2485804A4 (en) | 2009-10-07 | 2015-07-29 | Medivation Technologies Inc | SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS |
US8781912B2 (en) | 2011-03-15 | 2014-07-15 | Opera Solutions, Llc | Computer-based method and computer program product for setting floor prices for items sold at auction |
AU2012229123B2 (en) * | 2011-03-15 | 2017-02-02 | British Columbia Cancer Agency Branch | Methods of treating breast cancer with anthracycline therapy |
WO2013066440A1 (en) * | 2011-07-29 | 2013-05-10 | Medivation Prostate Therapeutics, Inc. | Treatment of breast cancer |
AU2012345789B2 (en) | 2011-11-30 | 2018-02-15 | British Columbia Cancer Agency Branch | Methods of treating breast cancer with taxane therapy |
EP2888594B1 (en) | 2012-08-23 | 2018-08-15 | The Regents of the University of Colorado, a body corporate | Method for determining breast cancer treatment |
US9175291B2 (en) * | 2012-10-11 | 2015-11-03 | Isis Pharmaceuticals Inc. | Modulation of androgen receptor expression |
WO2014075067A1 (en) | 2012-11-12 | 2014-05-15 | Nanostring Technologies, Inc. | Methods to predict breast cancer outcome |
US10679730B2 (en) * | 2013-05-28 | 2020-06-09 | The University Of Chicago | Prognostic and predictive breast cancer signature |
US10196693B2 (en) * | 2014-12-12 | 2019-02-05 | Medivation Prostate Therapeutics Llc | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer |
-
2015
- 2015-12-08 US US14/962,864 patent/US10196693B2/en active Active
- 2015-12-08 MX MX2017007707A patent/MX2017007707A/es unknown
- 2015-12-08 ES ES15831013T patent/ES2748005T3/es active Active
- 2015-12-08 BR BR112017012142A patent/BR112017012142A2/pt not_active IP Right Cessation
- 2015-12-08 EP EP19192143.6A patent/EP3604556A1/en active Pending
- 2015-12-08 CA CA2970469A patent/CA2970469A1/en active Pending
- 2015-12-08 EP EP15831013.6A patent/EP3230471B1/en active Active
- 2015-12-08 SG SG11201704425TA patent/SG11201704425TA/en unknown
- 2015-12-08 KR KR1020177019159A patent/KR20170095306A/ko unknown
- 2015-12-08 AU AU2015360767A patent/AU2015360767A1/en not_active Abandoned
- 2015-12-08 RU RU2017120330A patent/RU2017120330A/ru not_active Application Discontinuation
- 2015-12-08 JP JP2017531209A patent/JP6735277B2/ja active Active
- 2015-12-08 CN CN201580068041.7A patent/CN107109488A/zh active Pending
- 2015-12-08 WO PCT/US2015/064500 patent/WO2016094408A1/en active Application Filing
-
2017
- 2017-05-30 IL IL252587A patent/IL252587A0/en unknown
- 2017-06-07 ZA ZA2017/03904A patent/ZA201703904B/en unknown
-
2018
- 2018-12-10 US US16/215,340 patent/US11186876B2/en active Active
-
2021
- 2021-11-10 US US17/523,235 patent/US11952634B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20170095306A (ko) | 2017-08-22 |
IL252587A0 (en) | 2017-07-31 |
US20220056541A1 (en) | 2022-02-24 |
EP3230471B1 (en) | 2019-08-28 |
RU2017120330A (ru) | 2019-01-14 |
US10196693B2 (en) | 2019-02-05 |
ES2748005T3 (es) | 2020-03-12 |
US11952634B2 (en) | 2024-04-09 |
EP3604556A1 (en) | 2020-02-05 |
JP2018504892A (ja) | 2018-02-22 |
SG11201704425TA (en) | 2017-06-29 |
US11186876B2 (en) | 2021-11-30 |
EP3230471A1 (en) | 2017-10-18 |
CN107109488A (zh) | 2017-08-29 |
US20190169697A1 (en) | 2019-06-06 |
ZA201703904B (en) | 2019-12-18 |
CA2970469A1 (en) | 2016-06-16 |
BR112017012142A2 (pt) | 2018-01-02 |
US20160168646A1 (en) | 2016-06-16 |
WO2016094408A1 (en) | 2016-06-16 |
AU2015360767A1 (en) | 2017-06-08 |
MX2017007707A (es) | 2018-03-06 |
RU2017120330A3 (pt) | 2019-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6735277B2 (ja) | 乳癌療法剤に対する反応を予測するための方法および乳癌の処置の方法 | |
RU2739942C2 (ru) | Терапевтические, диагностические и прогностические способы для рака мочевого пузыря | |
KR102125496B1 (ko) | 파르네실전달효소 억제제를 이용하여 암환자를 치료하는 방법 | |
US20180147226A1 (en) | Methods and assays for combination treatment of cancer | |
US20190192517A1 (en) | Treatment of squamous cell carcinomas with inhibitors of erk | |
KR102604025B1 (ko) | 개인별 약물 치료 계획의 개발 방법 및 단백질체 프로파일을 기반으로 하는 표적 약물 개발 방법 | |
JP2021502071A (ja) | がんバイオマーカーおよびその使用方法 | |
JP2015530072A (ja) | ゲムシタビン療法による乳癌の治療方法 | |
WO2013052480A1 (en) | Marker-based prognostic risk score in colon cancer | |
JP2019534290A (ja) | 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤 | |
TW202023556A (zh) | 以mapk路徑抑制劑治療腺癌 | |
EP2188391A1 (en) | Predictive markers for egfr inhibitor treatment | |
US20230160016A1 (en) | Methods of selecting a treatment for cancer patients | |
JP7122016B2 (ja) | グリオーマの予後、遠隔部再発リスク及び浸潤を判定する方法及びキット並びにグリオーマを処置するための医薬組成物 | |
US20210085634A1 (en) | Methods of identifying and treating patients with hif-2 inhibitor resistance | |
JP2023500950A (ja) | マントル細胞リンパ腫(mcl)対象を特定するための鉄スコアおよびインビトロ方法ならびに治療的使用および方法 | |
JP6478417B2 (ja) | 大腸癌患者の生存を予測及び改善するための方法 | |
KR102431271B1 (ko) | 항암제 반응성 예측용 바이오마커 및 이의 용도 | |
KR20240023045A (ko) | 암 치료를 위한 진단 방법 및 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181210 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181210 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200427 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200625 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200713 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6735277 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |